Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Formed by a reverse merger between Zafgen, Inc. and Chondrial Therapeutics, Inc., the company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
| Headquarters | Bala Cynwyd, PA |
| Website | larimartx.com |
| Pipeline | Clinical |
| Larimar Therapeutics |